Abstract
<p class="Abstract">The main purpose of the current study was to study the antitumor effects of iridomyrmecin against human cervical cancer cells (HeLa). Its effects on apoptosis induction, cell cycle phase distribution, PI3K/Akt signalling pathway and long non-coding RNA (lncRNA) were also investigated. Cytotoxic effects of iridomyrmecin were evaluated by MTT assay while the apoptotic effect was assessed by flow cytometry using annexin V-FITC assay. Western blot assay was used to study effects on PI3K/Akt signalling pathway. Results exhibited that iridomyrmecin led to concentration-dependent as well as time-dependent growth inhibitory effects. Iridomyrmecin-treated cells showed signs of early and late apoptosis. Iridomyrmecin treatment also led to sub-G1 cell cycle arrest as well as induced loss of mitochondrial membrane potential (ΔΨm). Further, Western blot assay revealed that iridomyrmecin treatment resulted in down-regulation of PI3K/Akt protein expressions in a dose-dependent manner while as it up-regulated lncRNA CCAT2 expression.</p><p class="Abstract"><strong>Video Clip</strong>:</p><p class="Abstract"><a href="https://youtube.com/v/4mKwQAi3Qbk">Flow cytometry for cell cycle analysis</a>: 3 min 20 sec</p><p> </p>
Highlights
China represents one of the few countries with a very high occurrence of cervical cancer and is accountable for more than 45% of all the new cases diagnosed globally
The cytotoxic activity of iridomyrmecin in human cervical cancer cells (HeLa) cells is shown in Figure 1 which shows that iridomyrmecin exhibits significant cytotoxic effect in these cells
Iridomyrmecin induced early and late apoptosis in HeLa human cervical cancer cells Figure 2A-D show the effect of iridomyrmecin on apoptosis induction as well as its quantification using annexin V-fluorescein isothiocyanate (FITC) assay along with flow cytometry
Summary
China represents one of the few countries with a very high occurrence of cervical cancer and is accountable for more than 45% of all the new cases diagnosed globally. In China, cervical cancer is the third prominent cause of cancer related mortality (Chen et al, 2004; Shi et al, 2008; Wen, 2005). Helicobacter pylori infection remains one of the most prominent risk factors of cervical cancer (Fiedler et al, 2004). Cervical cancer treatment strategy involves a combination of surgical resection, radiotherapy and chemotherapy depending on the tumor location and size. Among the chemotherapeutic agents used against cervical cancer include 5-fluorouracil, leucovorin, cisplatin, epirubicin, capecitabine, oxaliplatin or their different combinations (Peter et al, 1999; Yoshihiro et al, 2000).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
